GSK's gepotidacin, a drug recently approved by the FDA for the management of uncomplicated urinary tract infections, has shown powerful efficacy against gonorrhea, a common sexually transmitted infection (STI). Recent findings published in The Lancet revealed that gepotidacin's success rate in eradicating this infection slightly outpaced standard treatment methodologies.
Notably, the phase 3 study, called EAGLE-1,…